(BANGKOK, Sep 12, 2011) Bionor Pharma presented Vacc-4x on “Global HIV Vaccine Enterprise” press conference at AIDS Vaccine 2011 in Bangkok. Results from Phase IIB Placebo Controlled Study of Bionor’s Vacc-4x show excellent safety profile and statistically significant viral load reduction in patients with HIV who suspend antiretroviral therapy. The vaccine, developed by Bionor Pharma, …
BioCentury Publications, Inc., a leading provider of value-added information on strategic issues in life science, has in their report BioCentury Week in Review Aug 29, 2011, published the clinical status of the upcoming clinical trial regarding Bionor’s therapeutic vaccine, Vacc-4x in combination with Revlimid®. Link to the reprint
Oslo – 25.08.11 – Bionor Pharma ASA Announces Exploratory Study of its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination with Leading Cancer Drug The study will determine: The target patient population for the study will be HIV-patients whose immune system have not fully recovered (defined by CD4+ (helper) T-cell count in the interval 250-400 cells …
